CN111670184B - 吡唑化合物及其制备方法 - Google Patents

吡唑化合物及其制备方法

Info

Publication number
CN111670184B
CN111670184B CN201980011350.9A CN201980011350A CN111670184B CN 111670184 B CN111670184 B CN 111670184B CN 201980011350 A CN201980011350 A CN 201980011350A CN 111670184 B CN111670184 B CN 111670184B
Authority
CN
China
Prior art keywords
methyl
difluoromethyl
compound
formula
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980011350.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111670184A (zh
Inventor
S·沙玛
D·詹吉德
P·达卡
S·马德瓦尔
B·库马尔
K·库马尔
R·安纳德
A·杰恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of CN111670184A publication Critical patent/CN111670184A/zh
Application granted granted Critical
Publication of CN111670184B publication Critical patent/CN111670184B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/72—Copper
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/08—Halides
    • B01J27/122—Halides of copper
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201980011350.9A 2018-02-01 2019-02-01 吡唑化合物及其制备方法 Active CN111670184B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN201811003855 2018-02-01
IN201811003859 2018-02-01
IN201811003859 2018-02-01
IN201811003855 2018-02-01
IN201711042921 2018-05-30
IN201711042921 2018-05-30
PCT/IN2019/050076 WO2019150392A1 (en) 2018-02-01 2019-02-01 Pyrazole compounds and preparation thereof

Publications (2)

Publication Number Publication Date
CN111670184A CN111670184A (zh) 2020-09-15
CN111670184B true CN111670184B (zh) 2026-07-10

Family

ID=67478207

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980011350.9A Active CN111670184B (zh) 2018-02-01 2019-02-01 吡唑化合物及其制备方法

Country Status (14)

Country Link
US (1) US11873289B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746434A4 (cg-RX-API-DMAC7.html)
JP (1) JP7402804B2 (cg-RX-API-DMAC7.html)
KR (1) KR102951622B1 (cg-RX-API-DMAC7.html)
CN (1) CN111670184B (cg-RX-API-DMAC7.html)
AU (1) AU2019213854C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020015692A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090204A1 (cg-RX-API-DMAC7.html)
IL (1) IL276410B2 (cg-RX-API-DMAC7.html)
MA (1) MA54677A (cg-RX-API-DMAC7.html)
MX (2) MX2020008151A (cg-RX-API-DMAC7.html)
MY (1) MY209060A (cg-RX-API-DMAC7.html)
SG (1) SG11202007328UA (cg-RX-API-DMAC7.html)
WO (1) WO2019150392A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54677A (fr) 2018-02-01 2021-11-17 Myokardia Inc Composés pyrazoles et leur préparation
WO2025244956A1 (en) * 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428719A (zh) * 2015-01-22 2017-12-01 迈奥卡迪亚公司 用于治疗扩张性心肌病(dcm)的4‑甲基磺酰基取代的哌啶脲化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007284386A (ja) 2006-04-18 2007-11-01 Kumiai Chem Ind Co Ltd 3−ピラゾリルフェニルスルフィド誘導体及びそれを有効成分として含有する殺虫・殺ダニ・殺線虫剤
US8324178B2 (en) 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
CN104703972B (zh) 2012-08-30 2017-05-31 拜耳农作物科学股份公司 3,5‑双(卤烷基)‑吡唑‑4‑甲酸衍生物的脱羧方法
WO2014089913A1 (zh) 2012-12-12 2014-06-19 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的并环化合物
EP3063134B1 (en) 2013-11-01 2020-08-12 Srf Limited Process for the preparation of pyrazole derivatives
EP3015458A1 (en) 2014-11-03 2016-05-04 Bayer CropScience AG Process for preparing 3,5-bis(haloalkyl)pyrazole derivatives from a,a-dihaloamines and ketimines
US11452717B2 (en) 2017-01-10 2022-09-27 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof
CN111132964A (zh) 2017-04-11 2020-05-08 欧瑞克制药公司 糖皮质激素受体调节剂
MA54677A (fr) 2018-02-01 2021-11-17 Myokardia Inc Composés pyrazoles et leur préparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428719A (zh) * 2015-01-22 2017-12-01 迈奥卡迪亚公司 用于治疗扩张性心肌病(dcm)的4‑甲基磺酰基取代的哌啶脲化合物

Also Published As

Publication number Publication date
EP3746434A4 (en) 2021-11-17
CA3090204A1 (en) 2019-08-08
IL276410B2 (en) 2024-09-01
IL276410B1 (en) 2024-05-01
MX2025003379A (es) 2025-05-02
MY209060A (en) 2025-06-18
JP2021512127A (ja) 2021-05-13
JP7402804B2 (ja) 2023-12-21
BR112020015692A2 (pt) 2020-12-08
AU2019213854C1 (en) 2023-12-14
US20210053940A1 (en) 2021-02-25
SG11202007328UA (en) 2020-08-28
KR102951622B1 (ko) 2026-04-13
AU2019213854A1 (en) 2020-09-03
MA54677A (fr) 2021-11-17
IL276410A (en) 2020-09-30
CN111670184A (zh) 2020-09-15
MX2020008151A (es) 2020-09-18
KR20200118025A (ko) 2020-10-14
AU2019213854B2 (en) 2023-06-15
WO2019150392A1 (en) 2019-08-08
US11873289B2 (en) 2024-01-16
EP3746434A1 (en) 2020-12-09

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40027579

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant